Replies to post #1824 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA 2020 clinical goals:

https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-to-Provide-Updates-on-its-RD-Programs-and-Business-Outlook-for-2020-during-the-38th-Annual-JP-Morgan-Healthcare-Conference/default.aspx

• RSV N-inhibitor EDP-938 and hMPV Inhibitor Leads

--Data from RSVP Phase 2b adult outpatient study in 3Q 2020 (if enrollment can be completed in one RSV season in northern hemisphere);

--Initiate Phase 2 dose ranging study in pediatric RSV patients in 4Q 2020;

--Initiate Phase 2 study in adult transplant patients with RSV in 4Q 2020;

--Perform optimization of Enanta’s current nanomolar hMPV inhibitor leads.


• HBV Core Inhibitor EDP-514

--Phase 1 data in healthy volunteers in 1Q 2020;

--Initiate Phase 1b in nuc-suppressed HBV patients in 1Q 2020;

--Initiate Phase 1b in viremic HBV patients in 2Q 2020.


• NASH / PBC FXR Agonists EDP-305 and EDP-297

--Initiate ARGON-2 Phase 2b study of EDP-305 in NASH by early 2Q 2020;

--Phase 2 data from INTREPID study of EDP-305 in PBC in 2Q 2020;

--Initiate Phase 1 study of EDP-297 (follow-on FXR) in mid-2020;

--Advance discovery of non-FXR compounds for NASH.